
    
      The primary objective of the study is to determinate the maximal tolerate dose and evaluate
      the toxicity of RAD 001 in patients older less than 65 years in AML relapse in association
      with a conventional chemotherapy 5Aracytine and Daunorubicine) in an dose escalated phase I
      study.
    
  